Literature DB >> 34788758

Variations in Radioiodine Therapy in Europe: Decision-Making after Total Thyroidectomy.

Flavio Forrer1, Galina Farina Fischer1,2, Ole Maas1, Luca Giovanella3,4, Martha Hoffmann5, Ioannis Iakovou6, Markus Luster7, Jasna Mihailovic8,9, Petra Petranovic Ovčariček10, Alexis Vrachimis11,12, Slimane Zerdoud13, Paul Martin Putora2,14.   

Abstract

The role of radioiodine therapy (RIT) (used as ablation therapy or adjuvant therapy) following total thyroidectomy for differentiated thyroid cancer (DTC) changed. Major revisions of the American Thyroid Association (ATA) Guidelines in 2015 resulted in significant differences in treatment recommendations in comparison to the European Association of Nuclear Medicine (EANM) 2008 guidelines. Recently, we presented the effects on daily practice for RIT among Swiss Nuclear Medicine centres. We now performed a study at the European level and hypothesized that there is also considerable variability among European experts. We performed a decision-tree-based analysis of management strategies from all members of the EANM thyroid committee to map current practice among experts. We collected data on whether or not RIT is administered, on which criteria these decisions are based and collected details on treatment activities and patient preparation. Our study shows discrepancies for low-risk DTC, where "follow-up only" is recommended by some experts, while RIT with significant doses is used by other experts. E.g., for pT1b tumours without evidence of metastases, the level of agreement for the use of RIT is as low as 50%. If RIT is administered, activities of I-131 range from 1.1 GBq to 3.0 GBq. In other constellations (e.g., pT1a), experts diverge from current clinical guidelines as up to 75% administer RIT in certain cases. For intermediate and high-risk patients, RIT is generally recommended. However, dosing and treatment preparation (rhTSH vs. thyroid hormone withdrawal) vary distinctly. In comparison to the Swiss study, the general level of agreement is higher among the European experts. The recently proposed approach on the use of RIT, based on integrated post-surgery assessment (Martinique article) and results of ongoing prospective randomized studies are likely to reduce uncertainty in approaching RIT treatment. In certain constellations, consensus identified among European experts might be helpful in formulating future guidelines.
© 2021 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Decision-making; Radioiodine; Radioiodine therapy; Thyroid cancer

Mesh:

Substances:

Year:  2021        PMID: 34788758      PMCID: PMC8985029          DOI: 10.1159/000520938

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  35 in total

1.  Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer.

Authors:  Frederik A Verburg; Cumali Aktolun; Arturo Chiti; Savvas Frangos; Luca Giovanella; Martha Hoffmann; Ioannis Iakovou; Jasna Mihailovic; Bernd J Krause; Werner Langsteger; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-17       Impact factor: 9.236

Review 2.  Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma.

Authors:  Ian D Hay
Journal:  J Surg Oncol       Date:  2006-12-15       Impact factor: 3.454

Review 3.  Controversial Issues in Thyroid Cancer Management.

Authors:  R Michael Tuttle
Journal:  J Nucl Med       Date:  2018-04-13       Impact factor: 10.057

Review 4.  Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes-the Pompe disease burden scale.

Authors:  Thomas Hundsberger; Benedikt Schoser; Daniela Leupold; Kai Michael Rösler; Paul Martin Putora
Journal:  J Neurol       Date:  2019-05-18       Impact factor: 4.849

5.  Multidisciplinary approach for risk-oriented treatment of low-risk papillary thyroid cancer in Switzerland.

Authors:  Henryk Zulewski; Luca Giovanella; Stefan Bilz; Emanuel Christ; Andreas Haldemann; Hans Steinert; Sabine Weidner; Daniel Oertli; Frédéric Triponez; Thomas Clerici; Anna Minder; Matthias Dettmer; Paul Komminoth
Journal:  Swiss Med Wkly       Date:  2019-01-27       Impact factor: 2.193

6.  Variations in radioiodine ablation: decision-making after total thyroidectomy.

Authors:  O Maas; F Forrer; M Maas; C M Panje; J Blautzik; M Brühlmeier; I Engel-Bicik; L Giovanella; A Haldemann; M E Kamel; S Kneifel; C Rottenburger; N Schaefer; M A Walter; S Weidner; P M Putora
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-09       Impact factor: 9.236

7.  Diagnostic Nodes of Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Among Colorectal Cancer Patients: A Swiss National Multicenter Survey.

Authors:  Thomas Steffen; Paul Martin Putora; Martin Hübner; Beat Gloor; Kuno Lehmann; Christoph Kettelhack; Michel Adamina; Ralph Peterli; Jan Schmidt; Frédéric Ris; Markus Glatzer
Journal:  Clin Colorectal Cancer       Date:  2019-06-26       Impact factor: 4.481

Review 8.  Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer.

Authors:  Anna M Sawka; Kullathorn Thephamongkhol; Melissa Brouwers; Lehana Thabane; George Browman; Hertzel C Gerstein
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

9.  Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes.

Authors:  Christian Rothermundt; Alexandra Bailey; Linda Cerbone; Tim Eisen; Bernard Escudier; Silke Gillessen; Viktor Grünwald; James Larkin; David McDermott; Jan Oldenburg; Camillo Porta; Brian Rini; Manuela Schmidinger; Cora Sternberg; Paul M Putora
Journal:  Oncologist       Date:  2015-08-03

10.  Applied Swarm-based medicine: collecting decision trees for patterns of algorithms analysis.

Authors:  Cédric M Panje; Markus Glatzer; Joscha von Rappard; Christian Rothermundt; Thomas Hundsberger; Valentin Zumstein; Ludwig Plasswilm; Paul Martin Putora
Journal:  BMC Med Res Methodol       Date:  2017-08-16       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.